The company focuses on compounded GLP-1 medications, specifically compounded semaglutide and compounded tirzepatide, which are prescribed under physician supervision and shipped directly to patients
Currently, there is no universally established safe level for either substance, as the appropriate levels will largely depend on the users health status and specific medical needs
Limitations Consumer-grade tracking : Oura is not clinical-quality equipment
Obesity indication approval expanded GLP-1 addressable market by an estimated 10-15: The US obesity drug market was approximately USD 2 billion in 2021 before Wegovy's approval
Results can vary from person to person, depending on factors like diet, physical activity, medication adherence, and starting body weight
RetaLABS Tirzepatide 15mg is the entry-format lyophilised research vial of LY3298176, a dual GLP-1 and GIP receptor agonist developed by Eli Lilly, the first compound in the "twincretin" class